| Literature DB >> 30090084 |
Fan Jiang1, Tiansong Yang2, Hongna Yin1, Yuhuai Guo1, Hiroki Namba3, Zhongren Sun1, Tetsuya Asakawa3,4.
Abstract
Acupuncture is an alternative therapy for Parkinson's disease (PD), but its efficacy and safety are controversial. Our previous study, which reviewed the literature from 1974 to 2012, could not find enough evidence from rigorously designed randomized, controlled trials (RCTs) to make a conclusion about the efficacy of acupuncture. Recently, more RCTs and meta-analyses have been conducted to evaluate the efficacy of acupuncture. The aim of our current study is to provide updated information in brief on this topic. In this study, we analyzed and summarized seven RCTs and four meta-analyses. Although all included studies were not of high quality, we found that there has been a tremendous progress in acupuncture research in treating Parkinson's disease (PD) during the past 5 years, based on our experience and insights into the behavioral assessments of PD. First, the numbers of RCTs and meta-analyses based on RCTs are increasing. Second, non-motor symptoms are increasingly emphasized. Third, objective behavioral assessment tools are being employed. Although recent studies can provide limited evidence for the efficacy of acupuncture, we make the following recommendations for the future investigation: First, large, multicenter, well-designed RCTs should be organized for evaluation of the efficacy of acupuncture. Second, objective assessments using novel computerized technologies should be considered. Third, target symptoms should be selected and evaluated instead of only performing global evaluations. Fourth, attention should be paid to the efficacy of scalp acupuncture. Fifth, the safety of acupuncture should be evaluated and reported.Entities:
Keywords: Parkinson's disease; acupuncture; behavioral assessment; efficacy/safety; electroacupuncture; non-motor symptoms
Year: 2018 PMID: 30090084 PMCID: PMC6068266 DOI: 10.3389/fneur.2018.00596
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Information of the included literatures. (A) Flow chart of the literature selection protocol. PD, Parkinson's disease; RCT, randomized, controlled trial; WHO, World Health Organization. (B) Quality evaluation of included studies. OQAQ, Overview Quality Assessment Questionnaire. Strengths: E, Good searching strategy including enough RCTS; QE, Qualify of involved RCTs was evaluated; PA, Placebo acupuncture. Weaknesses: SB, Selection bias; RB, reporting bias; PB, Publication bias; SS, Small samples; NR, Adverse events unreported; NS, No sensitivity analysis NF, No follow up.
Efficacy and safety in the current acupuncture study.
| Lee et al. ( | A1. SA+CT vs. B1. CT alone | 184 participants including 4 RCTs | MS (4, 6, 8, 9, 14), MCA, CTCA, FMSA | >5 weeks average | UPDRS total score | No serious adverse events reported | A1 > B1, |
| Lee et al. ( | A1. Acup + CT vs. B1. CT alone | 1616 participants including 25 RCTs | Taichong (LR-3), Baihui (GV-20), Yanglingquan (GB-34), Fengchi (GB-20), Hegu (LI-4), Sishencong (EX-HN1), Quchi (LI-11) (Freq ≥ 7) | > 6 weeks average | UPDRS I | Unreported | 1: A1 > B1, |
| Liu et al. ( | A. Acup + Madopar vs. B. Madopar alone | 831 participants including 11 RCTs | Unreported | Unreported | Total efficacy | No serious adverse events reported | 1: A > B, |
| Noh et al. ( | A1. Acup+CT vs. B1. CT alone | 2625 participants including 42 RCTs | Taichong (LR-3), Fengchi (GB-20), Yanglingquan (GB-34), Hegu (LI-4), | > 4 weeks average | UPDRS total score | No serious adverse events reported | 1: A1 > B1, |
| Aroxa et al. | A. Acup + drug vs. B. drug alone | 22 participants | Taichong (LR-3), Sanyinjiao (SP-6), Hegu (LI-4), | 8 weeks | PDSS score | Unreported | A > B, |
| Cho et al. ( | Acup + BVA vs. | 63 participants | Fengchi (GB-20), | 12 weeks | UPDRS II | No serious adverse events reported | 1: A > C, |
| Kluger et al. ( | A. Acup vs. B. | 89 participants | Baihui (GV-20), Shenting (GV-24), | 6 weeks | MFIS: Total | No serious adverse events reported | 1: A > B, |
| Lei et al. ( | A. EA vs. B. | 15 participants | FMSA, BA, Baihui (GV-20), Dazhui (GV-14), Hegu (LI-4), Zusanli (ST-36), Yanglingquan (GB-34), Weizhong (BL-40), Sanyinjiao (SP-6), Taixi (KI-3), Taichong (LR-3) | 3 weeks | Gait-Speed | No serious adverse events reported | 1: A > B, |
| Wang 2015 ( | A. EA + drug vs. B. drug alone | 50 participants | Fengchi (GB-20), | 2 months | UPDRS III | Unreported | 1: A > B, |
| Liang and Chen ( | A. Acup vs. B. drug | 70 participants | Fengchi (GB-20), Wangu (GB-12), Tianzhu (BL-10), Yamen (GV-15) | 6 months | PDQ-39 | Unreported | 1: A > B, |
| Zhao 2017 ( | A. Acup + drug vs. B. drug | 108 participants | Taichong (LR-3), Fengchi (GB-20), Hegu (LI-4), | 3 months | UPDRS total scores | No serious adverse events reported | 1: A > B, |
p < 0.05;
p < 0.01.